02:23 PM EST, 11/17/2025 (MT Newswires) -- KDA Group ( KDAGF ) said Monday it opened its U.S. subsidiary ahead of the company launching its therapeutic monitoring platform for oncology, Medherize, next year

Medherize is a software-as-a-service (SAAS) that improves treatment adherence, inter-professional coordination, and the collection of real-world clinical data. Already deployed at a hospital in Quebec, the solution has proven effective in monitoring complex oral treatments and reducing therapy discontinuations, a statement said.

KDA's U.S. subsidiary will allow Medherize to be adapted to local healthcare infrastructures, particularly through ongoing analysis and integration with American laboratory systems.

"Our direct presence in the United States marks a pivotal step in our international expansion," said Marc Lemieux, chief executive officer.

"Medherize addresses a universal challenge: the efficient management and monitoring of specialty oral treatments. The U.S. market is many times larger than ours, representing a major lever to showcase our technology and pharmaceutical partnerships across North America," Lemieux added.

KDA shares last traded on Friday, closing at $0.26 per share on the TSX Venture Exchange.